含呋喃唑酮方案治疗幽门螺杆菌感染的研究进展

Recearch progress on the furazolidone regimen in treatment of Helicobacter pylori infection

近年来国内外幽门螺旋杆菌的感染率逐渐上升,各种因素下中国成为幽门螺杆菌感染的大国,同时抗生素的广泛使用使得幽门螺杆菌耐药形式也非常严峻,因而耐药率始终在低位的呋喃唑酮在根除治疗中逐渐显现出重要的意义。尽管该药近期因不良反应风险被限制应用于幽门螺杆菌之外的其他感染,但临床研究发现含有该药的三联疗法和四联疗法在幽门螺杆菌初次治疗和补救治疗中不仅能够获得更高的根除率,而且具有良好的安全性。因此,合理使用呋喃唑酮方案,对于幽门螺杆菌感染,尤其是高耐药背景下的幽门螺杆菌根除仍然具有临床价值。

In recent years,the infection rate of Helicobacter pylori(HP)has gradually increased,and China has become a major country of HP infection under various factors.At the same time,the widespread use of antibiotics makes HP’s resistance form very severe.Therefore,the resistance rate of furazolidone,which is always at a low level,gradually shows an important significance in eradication therapy.Although the drug has recently been restricted to other infections than HP due to the risk of adverse reactions.Clinical studies have found that triple therapy and quadruple therapy with furazolidone not only achieve higher eradication rates in HP initial treatment and remedial treatment,also it has good security.Therefore,the rational use of furazolidone regimen has clinical value for HP infection,especially HP eradication in the context of high drug resistance.